

1003 Rec'd PCT/PTO 0 2 FEB 2005

10/507081 PATENT

ATTORNEY DOCKET NO.: 056291-5178

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

NEWCOMBE et al.

Application No.: 10/507,081

Filed: September 9, 2004

FOR: DERIVATIVES OF 4-(IMIDAZOL-5-YL)-2-
(4-SULFOANILINO) PYRIMIDINE WITH
CDK INHIBITORY ACTIVITY

)
)
)
)
) Group Art Unit:

)
) Examiner:

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop _____
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Date: February 2, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

Attached is a Form PTO-1449 listing the enclosed foreign patent documents.

Copies of the U.S. patent documents are not enclosed.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.

Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 056291-5178 and proceed to consider this IDS.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.


Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Except for issue fees payable under 37 C.F.R. §1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP

Date: February 2, 2005
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk

By:


Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date: February 2, 2005	Attorney Docket No.	Client Ref.
	056291-5178	
	Applicant: NEWCOMBE et al.	
	Appln. No.: 10/507,081	
	Filing Date: September 9, 2004	
Examiner: Unassigned		Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR						
	BR						
	CR						
	DR						
	ER						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclosed	No
	FR	00/17203	03/2000	WO	Hirst et al.				
	GR	00/21926	04/2000	WO	Markwalder et al.				
	HR	00/25780	05/2000	WO	Liu et al.				
	IR	00/26209	05/2000	WO	Revesz				
**	JR	00/39101	06/2000	WO	Bradbury et al.				
	KR	00/44750	08/2000	WO	Lum et al.				
	LR	00/49018	08/2000	WO	Imbach et al.				
**	MR	00/53595	09/2000	WO	Breault et al.				
	NR	00/55161	09/2000	WO	Trova et al.				
**	OR	00/59892	10/2000	WO	Breault et al.				
	PR	00/78731 A1	12/2000	WO	Batchelor et al.				
	QR	01/29009 A1	04/2001	WO	Davis et al.				
	RR	01/30778 A1	05/2001	WO	Révész et al.				
	SR	01/37835 A1	05/2001	WO	Adams et al.				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	TR				
	UR				
	VR				

Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.